Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Ro 5126766

SKU: orb1300300

Description

RO5126766 (CH5126766) is a dual RAF/MEK inhibitor currently in Phase 1 clinical development. It potently inhibits BRAF V600E, BRAF, CRAF, and MEK1 with IC50 values ranging from 8.2 nM to 160 nM. This compound is a valuable research tool for investigating the MAPK pathway in both in vitro and in vivo cancer models.

Research Area

Signal Transduction

Images & Validation

Key Properties

CAS Number946128-88-7
MW471.46
Purity98.81% (May vary between batches)
FormulaC21H18FN5O5S
SMILESCNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F
TargetMEK,Raf
Solubility10% DMSO+40% PEG300+5% Tween-80+45% Saline:5 mg/mL (10.61 mM);DMSO:87 mg/mL (184.53 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

Target IC50
B-Raf (V600E):8.2 nM|B-Raf:19 nM|Raf:56 nM|MEK1:160 nM
In Vivo
In an HCT116 (G13D KRAS) mouse xenograft model, CH5126766 (25 mg/kg, p.o.) inhibits ERK signaling output more effectively than a standard MEK inhibitor that induces MEK phosphorylation and has potent antitumor activity. In the HCT116 (K-ras) and COLO205 (B-raf) mutant xenografts, CH5126766 (0.3 mg/kg) causes significant decreases in [18 F]FDG uptake. In the SK-MEL-2 xenograft model, RO5126766 also suppresses the tumor growth.
In Vitro
In HCT116 KRAS-mutant colorectal cancer cells, CH5126766 significantly reduces the levels of phospho-MEK and phospho-ERK. CH5126766 inhibits RAF kinase by binding to MEK1, and causes MEK to become a dominant negative inhibitor of RAF. In Raf or RAS-mutant cell lines SK-MEL-28, SK-MEL-2, MIAPaCa-2, SW480, HCT116, and PC3 cells, CH5126766 inhibits cell growth with IC50 of 65, 28, 40, 46, and 277 nM, respectively. In two melanoma cell lines with the BRAF V600E or NRAS mutation, RO5126766 induces G1 cell cycle arrest accompanied by up-regulation of the CDK inhibitor p27 and down-regulation of cyclinD1.
Cell Research
The number of viable cells is determined using the Cell Counting Kit-8 assay according to the manufacturer's instructions. After the incubation of cells for 72 h with the indicated concentrations of various agents, kit reagent WST-8 is added to the medium and incubated for a further 4 h. The absorbance of samples (450 nm) is determined using a scanning multiwell spectrophotometer that serves as an ELISA reader. Cell numbers and viability are also measured using the ViaCount Assay according to the manufacturer's instructions.(Only for Reference)

Storage & Handling

Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

inhibit, Mitogen-activated protein kinase kinase, MAP2K, MAPKK, MEK1, MEK, Inhibitor, C-Raf, CH5126766, CH-5126766, CH 5126766, Avutometinib, B-Raf (V600E), B-Raf, RO5126766, RO-5126766, Ro-5126766, Ro 5126766, Raf kinases, Raf, VS-6766
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Protocol Information

Available Sizes

Select a size below

1 mg
$ 100.00
2 mg
$ 120.00
5 mg
$ 160.00
1 ml x 10 mM (in DMSO)
$ 170.00
10 mg
$ 230.00
25 mg
$ 390.00
50 mg
$ 600.00
100 mg
$ 840.00
DispatchUsually dispatched within 5-10 working days
Bulk Enquiry